Your browser doesn't support javascript.
loading
Outcomes of patients with alcohol-associated hepatitis and acute kidney injury - Results from the HRS Harmony Consortium.
Ma, Ann T; Allegretti, Andrew S; Cullaro, Giuseppe; Ouyang, Tianqui; Asrani, Sumeet K; Chung, Raymond T; Przybyszewski, Eric M; Wilechansky, Robert M; Robinson, Jevon E; Sharma, Pratima; Simonetto, Douglas A; Jalal, Prasun; Orman, Eric S; Wadei, Hani M; St Hillien, Shelsea A; Saly, Danielle; Ufere, Nneka N; Dageforde, Leigh Anne; Regner, Kevin R; Belcher, Justin M; Patidar, Kavish R.
Affiliation
  • Ma AT; Toronto Centre for Liver Disease, University Health Network, Toronto, Ontario, Canada.
  • Allegretti AS; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cullaro G; Division of Gastroenterology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.
  • Ouyang T; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Asrani SK; Baylor University Medical Center, Dallas, Texas, USA.
  • Chung RT; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Przybyszewski EM; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Wilechansky RM; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Robinson JE; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Sharma P; Department of Internal Medicine, University of Michigan Health, Ann Arbor, Michigan, USA.
  • Simonetto DA; Division of Gastroenterology and Transplant Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jalal P; Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Orman ES; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Wadei HM; Department of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
  • St Hillien SA; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Saly D; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Ufere NN; Liver Center, Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Dageforde LA; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Regner KR; Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Belcher JM; Section of Nephrology, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
  • Patidar KR; CT and VA Connecticut Healthcare, West Haven, Connecticut, USA.
Article in En | MEDLINE | ID: mdl-39010302
ABSTRACT
BACKGROUND &

AIMS:

The development of acute kidney injury (AKI) in the setting of alcohol-associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown.

METHODS:

Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non-AH groups.

RESULTS:

A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End-stage Liver Disease-Sodium (MELD-Na) scores on admission. AKI phenotypes significantly differed between groups (p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90-day cumulative incidence of death (45% [95% CI 39%-51%] vs. 38% [95% CI 35%-40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90-day mortality was higher for AH (sHR 1.24 [95% CI 1.03-1.50], p = 0.024), but was not significant when adjusting for MELD-Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90-day mortality (sHR 1.82 [95% CI 1.16-2.86], p = 0.009).

CONCLUSIONS:

Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90-day mortality than those without AH, but this may have been driven by higher MELD-Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Canada

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Canada